+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are studying approximately 240 adult patients in Kazakhstan who have HER2-positive metastatic breast cancer mBC and are receiving anti-HER2 therapy, excluding trastuzumab deruxtecan. This observational retrospective study aims to evaluate real-world treatment approaches, clinical outcomes, and patient characteristics across 12 oncology centers to provide a representative sample of this population. The study covers patients diagnosed with mBC between January 2022 and December 2023 and includes a follow-up period to assess treatment impact. The study collects data retrospectively from patient medical records starting from the date of mBC diagnosis until either the patients death or the end of the study, which is at least 12 months after the latest diagnosis date. The treatments under review include all anti-HER2 therapies except trastuzumab deruxtecan. Researchers will analyze treatments received, diagnostic methods, therapy discontinuation reasons, lines of anticancer therapy, and efficacy in routine clinical practice. Participants data will be reviewed for at least 24 months following diagnosis, unless the patient died, moved, or refused therapy within that period. The primary outcome is to assess median progression-free survival and its rate over up to two years. Secondary outcomes include describing patient demographics, diagnostic and therapeutic patterns, treatment approaches, efficacy, reasons for stopping therapy, and number of therapy lines. This design involves no direct intervention, and data collection is based on existing medical records.

Age: 18Years - 99YearsAll Genders
12 locations
I

Actively Recruiting

Researchers are evaluating the real-world effects of adding anifrolumab to standard treatment for patients with Systemic Lupus Erythematosus SLE. This multi-country observational study aims to gather important information on how anifrolumab works in routine clinical practice across various countries, including those in the Gulf Cooperation Council, Latin America, Taiwan, and Egypt. The study uses standardized criteria and assessments to compare results across these locations. Participants who have been prescribed anifrolumab for the first time will be followed prospectively for one year after their initial infusion. The study also collects data from the year before starting anifrolumab to understand baseline health status. Clinical assessments relevant to SLE, including specific measures for skin symptoms, are used to monitor the patients. The study continues to collect data even if patients stop anifrolumab treatment, unless they withdraw consent. During the study, participants will undergo clinical and patient-reported evaluations at baseline and multiple points over one year, including assessments like PGA, SLEDAI-2K, CLASI, FACIT-Fatigue, LupusQoL, and EQ-5D-5L. Researchers will monitor these outcomes to understand how patients respond to anifrolumab in everyday care. The study period continues until the end of 2027 or until patients discontinue participation, with careful follow-up to capture ongoing health information.

Age: 18Years +All Genders
32 locations